Phaseline

Companies › Betta Pharmaceuticals

Betta Pharmaceuticals: clinical trials, targets and expected readouts

9 active drug programs in 27 registered trials: 13 Phase 1, 13 Phase 2, 1 Phase 3; Oncology, Other, Gastroenterology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Befotertinib
EGFR tyrosine kinase inhibitor
EGFRPhase 3Non-Small Cell Lung Cancer; NSCLC; DDI (Drug-Drug Interaction); Non-small Cell Lung Cancer (NSCLC) …Apr 2027
BPI-371153
PD-L1 inhibitor
CD274Phase 1Advanced Solid TumorDec 2026
X-82
Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor
PDGFRB, PDGFRA, FLT1, FLT4, KDRPhase 1DDI (Drug-Drug Interaction); Hepatic Impairment (HI); Advanced Non-small Cell Lung Cancer (NSCLC); Vorolanib …Jan 2027
CFT8919
EGFR tyrosine kinase inhibitor
EGFRPhase 1Non-Small Cell Lung Cancer With EGFR MutationJun 2027
MCLA-129
bispecific antibody targeting EGFR and cMET
EGFR, METPhase 1Solid Tumor; Solid Advanced TumorApr 2028
BPI-572270
RAS mutant inhibitor
–Phase 1Non-small Cell Lung Cancer (NSCLC)Dec 2028
Ensartinib
ALK tyrosine kinase receptor inhibitor
ALKPhase 1Solid Advanced Tumor; Nonsmall Cell Lung Cancer; Non-Small Cell Lung Cancer; Advanced Malignant Solid Neoplasm …Feb 2029
BPI-16350–Phase 1Advanced Solid Cancer–
BPI-460372–Phase 1Advanced Solid Tumor–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05789602BPI-460372Phase 1Advanced Solid TumorOncologyApr 2025
NCT03753685EnsartinibPhase 2Nonsmall Cell Lung CancerOncologyJun 2025
NCT03791112BPI-16350Phase 1Advanced Solid CancerOncologyDec 2025
NCT06728852X-82Phase 2Advanced Non-small Cell Lung Cancer (NSCLC)OncologyDec 2026
NCT05491811EnsartinibPhase 2Non-Small Cell Lung CancerOncologyDec 2026
NCT05341557BPI-371153Phase 1Advanced Solid TumorOncologyDec 2026
NCT07386158X-82Phase 2VorolanibOncologyDec 2026
NCT03155620EnsartinibPhase 2Advanced Malignant Solid NeoplasmOncologyJan 2027
NCT07809789X-82Phase 1DDI (Drug-Drug Interaction)OtherJan 2027
NCT03420508EnsartinibPhase 2MelanomaOncologyJan 2027
NCT05241028EnsartinibPhase 2Non-small Cell Lung CancerOncologyFeb 2027
NCT07809815BefotertinibPhase 1DDI (Drug-Drug Interaction)OtherApr 2027
NCT06641609CFT8919Phase 1Non-Small Cell Lung Cancer With EGFR MutationOncologyJun 2027
NCT07809802X-82Phase 1Hepatic Impairment (HI)GastroenterologyJun 2027
NCT04837716EnsartinibPhase 1Metastatic Lung Non-Small Cell CarcinomaOncologySep 2027
NCT03213652EnsartinibPhase 2Advanced Malignant Solid NeoplasmOncologyOct 2027
NCT06730672X-82Phase 2Renal Cell Carcinoma Stage IOncologyDec 2027
NCT06728865BefotertinibPhase 2Non-small Cell Lung Cancer (NSCLC)OncologyFeb 2028
NCT07354061EnsartinibPhase 1NSCLC (Non-small Cell Lung Cancer)OncologyMar 2028
NCT04930432MCLA-129Phase 1Solid TumorOncologyApr 2028
NCT06041776BefotertinibPhase 3Non-Small Cell Lung CancerOncologyApr 2028
NCT07181499BefotertinibPhase 2NSCLCOncologyNov 2028
NCT07435038BPI-572270Phase 1Non-small Cell Lung Cancer (NSCLC)OncologyDec 2028
NCT07448116MCLA-129Phase 1Solid Advanced TumorOncologyFeb 2029
NCT07448116EnsartinibPhase 1Solid Advanced TumorOncologyFeb 2029
NCT07047001X-82Phase 2Renal Cell Carcinoma (RCC)OncologyJun 2029
NCT07709585BefotertinibPhase 2Advanced Non-small Cell Lung Cancer (NSCLC)OncologyJul 2030

Targets

EGFR (3) MET (1) PDGFRB (1) PDGFRA (1) FLT1 (1) FLT4 (1) KDR (1) ALK (1) CD274 (1)

Companies with the same targets

AstraZeneca Chia Tai Tianqing Pharmaceutical Group Shanghai Henlius Biotech Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Jiangsu HengRui Medicine Novartis Avalyn Pharma Mannkind Hutchmed

Companies built like this

Avistone Biotechnology Abbisko Therapeutics Nanjing Sanhome Pharmaceutical Pierre Fabre Medicament Hansoh BioMedical R&D Company

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.